IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CORSINI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 27.315
AS - Asia 22.519
NA - Nord America 20.673
SA - Sud America 2.182
AF - Africa 451
OC - Oceania 184
Continente sconosciuto - Info sul continente non disponibili 18
Totale 73.342
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.762
CN - Cina 7.861
GB - Regno Unito 7.439
DE - Germania 5.587
IT - Italia 5.461
SG - Singapore 5.421
RU - Federazione Russa 1.808
HK - Hong Kong 1.732
BR - Brasile 1.575
SE - Svezia 1.442
VN - Vietnam 1.391
IN - India 1.184
FR - Francia 1.097
BD - Bangladesh 1.051
JP - Giappone 853
NL - Olanda 778
TR - Turchia 747
KR - Corea 701
IE - Irlanda 588
FI - Finlandia 577
CA - Canada 496
UA - Ucraina 462
ID - Indonesia 391
ES - Italia 389
MX - Messico 275
PL - Polonia 234
EU - Europa 230
DK - Danimarca 210
AR - Argentina 183
TW - Taiwan 182
GR - Grecia 165
AT - Austria 162
BE - Belgio 156
AU - Australia 149
CO - Colombia 148
TH - Thailandia 137
CH - Svizzera 132
RO - Romania 127
EG - Egitto 112
PH - Filippine 103
IQ - Iraq 93
PT - Portogallo 93
CL - Cile 88
ZA - Sudafrica 84
IL - Israele 79
IR - Iran 78
CZ - Repubblica Ceca 73
MY - Malesia 73
SA - Arabia Saudita 73
PK - Pakistan 71
CI - Costa d'Avorio 62
SI - Slovenia 57
EC - Ecuador 49
RS - Serbia 49
VE - Venezuela 49
PE - Perù 43
JO - Giordania 36
UZ - Uzbekistan 34
DZ - Algeria 33
NZ - Nuova Zelanda 31
AE - Emirati Arabi Uniti 30
HU - Ungheria 30
TN - Tunisia 30
HR - Croazia 29
NO - Norvegia 24
PS - Palestinian Territory 24
MA - Marocco 22
NP - Nepal 22
JM - Giamaica 20
KZ - Kazakistan 20
LB - Libano 20
PY - Paraguay 20
DO - Repubblica Dominicana 19
SC - Seychelles 19
AZ - Azerbaigian 18
EE - Estonia 18
LU - Lussemburgo 18
BG - Bulgaria 17
KE - Kenya 17
LT - Lituania 14
AL - Albania 12
BY - Bielorussia 12
HN - Honduras 12
MD - Moldavia 12
PA - Panama 12
UY - Uruguay 12
CR - Costa Rica 11
NG - Nigeria 11
OM - Oman 11
ET - Etiopia 10
GT - Guatemala 10
TT - Trinidad e Tobago 10
BA - Bosnia-Erzegovina 9
BO - Bolivia 9
LV - Lettonia 9
AM - Armenia 8
SK - Slovacchia (Repubblica Slovacca) 8
SY - Repubblica araba siriana 8
BH - Bahrain 7
CY - Cipro 7
Totale 73.377
Salva come PNG Salva come JPEG
Città #
Southend 6.586
Singapore 3.176
Hanover 3.129
Ashburn 1.780
Hong Kong 1.481
Milan 1.451
Chandler 1.171
San Jose 1.156
Beijing 1.151
Seattle 828
Council Bluffs 795
Frankfurt am Main 721
Fairfield 686
Princeton 673
Dallas 665
Wilmington 650
Dublin 572
Los Angeles 553
Houston 530
Santa Clara 503
Ann Arbor 455
Shanghai 401
New York 397
Guangzhou 390
Nanjing 381
Redwood City 373
Ho Chi Minh City 372
Woodbridge 338
Mountain View 337
Lauterbourg 332
Redmond 325
Bengaluru 317
Rome 309
Hefei 301
Moscow 292
Hanoi 289
Boardman 282
Tokyo 281
Buffalo 278
Dearborn 266
Helsinki 257
Des Moines 228
São Paulo 224
Grafing 221
Jakarta 219
Cambridge 214
Istanbul 202
Jacksonville 195
Changsha 187
Jinan 182
Sakarya 179
Tianjin 170
The Dalles 168
Shenyang 164
Seoul 161
Dong Ket 156
Toronto 151
Berlin 150
Columbus 148
Sunnyvale 145
Boise 138
Hangzhou 132
Cangzhou 122
Wuhan 121
Munich 119
Chengdu 115
Parma 115
Phoenix 111
Zhengzhou 111
Nanchang 108
Serra 106
Hebei 104
Eitensheim 103
Naples 103
Atlanta 94
Bogotá 94
Shenzhen 94
Chicago 93
Athens 92
London 92
Warsaw 90
Taipei 83
Washington 83
Nuremberg 80
Andover 78
Vienna 78
Madrid 77
Turin 75
Bologna 74
Fuzhou 74
Brussels 73
Somerville 73
Mumbai 72
San Diego 67
Ottawa 66
Jiaxing 64
Bangkok 63
Florence 63
Abidjan 61
Padova 58
Totale 42.313
Salva come PNG Salva come JPEG
Nome #
PCSK9 inhibition and inflammation: A narrative review 1.833
NAFLD or MAFLD diagnoses and cardiovascular diseases: from epidemiology to drug approaches 1.444
Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9 1.216
Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease 1.097
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice 907
Safety of statins: focus on clinical pharmacokinetics and drug interactions 860
The role of mitochondria in statin-induced myopathy 831
Recent advances in synthetic pharmacotherapies for dyslipidaemias 819
In Vitro Angiogenesis Inhibition with Selective Compounds Targeting the Key Glycolytic Enzyme PFKFB3 796
OMEGA-3 AND CARDIOVASCULAR PREVENTION - IS THIS STILL A CHOICE? 711
PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement 687
Bococizumab for the treatment of hypercholesterolaemia 645
Suppressor of Cytokine Signaling-3 (SOCS-3) induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) expression in hepatic HepG2 cell line 638
LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters 603
The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice 595
Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents 588
Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes? 519
Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9: The Role of STAT3 512
A new dawn for managing dyslipidemias: The era of rna-based therapies 462
Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells 450
Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs) 449
Identificazione di nuovi inibitori selettivi della proteina Rac1: possibili implicazioni farmacologiche 448
Clinical approach to the inflammatory etiology of cardiovascular diseases 438
Present therapeutic role of cholesteryl ester transfer protein inhibitors 429
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation 420
PCSK9 induces a pro-inflammatory response in macrophages 416
Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review 408
PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin 407
Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake 398
Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease 380
Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists 374
Effect of the histone deacetylase inhibitor tricostatin A on lipid metabolsm, TNF-ALPHA production and smoth muscle cell proliferation 372
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis society consensus panel statement on assessment, aetiology and management 365
High density lipoprotein function is reduced in patients affected by genetic or idiopathic hypogonadism 347
ABCA1 and HDL3 are required to modulate smooth muscle cells phenotypic switch after cholesterol loading 346
Raloxifene elicits combined rapid vasorelaxation and long-term anti-inflammatory actions in rat aorta 344
PPAR-α agonists are still on the rise: an update on clinical and experimental findings 333
Adverse effects of statin therapy : perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract 328
Drug interactions in cardiology: focus on statins and their combination with other lipid-lowering drugs 327
Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome 322
Statin drug interactions and related adverse reactions : an update 317
The dataset describes : phenotypic changes induced by cholesterol loading in smooth muscle cells isolated from the aortae of C57BL/6 mice 301
Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals 300
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: similarities and differences 298
Prevention Italy 2021 - An update of the 2018 Consensus document and recommendations for the prevention of cardiovascular disease in Italy 298
Are pleiotropic effects of statins real? 294
Maternal exposure to air pollutants, PCSK9 levels, fetal growth and gestational age – An Italian cohort 293
Off-label use of reduced dose direct oral factor Xa-inhibitors in subjects with atrial fibrillation: a review of clinical evidence 290
Polymorphonuclear leukocyte–myocyte interaction : an early event in collar-induced rabbit carotid intimal thickening 289
Inhibition of the Key Glycolytic Enzyme PFKFB3 with Novel Compounds Suppresses Vessel Sprouting 285
Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency 280
Angiogenesis inhibition with novel compounds targeting the key glycolytic enzyme PFKFB3 275
Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity 267
Interazioni tra leucociti polimorfonucleati e monociti : un evento primario nell'ispassimento intimale indotto dall'applicazione del collarino alla caraotide di coniglio 263
Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation 263
Identificazione di nuovi inibitori selettivi della proteina Rac1: possibili implicazioni farmacologiche 262
Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells 259
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels 257
Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation 255
Statins plus ezetimibe in the era of proprotein convertase subtilisin/kexin type-9 inhibitors 252
Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation 250
Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression 249
Perivascular carotid collar placement induces neointima formation and outward arterial remodeling in mice independent of apolipoprotein E deficiency or Western-type diet feeding 246
Oxidized LDL-dependent pathway as new pathogenic trigger in arrhythmogenic cardiomyopathy 246
Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits 245
ABCA1 and HDL3 are required to modulate smooth muscle cells phenotypic switch after cholesterol loading 244
NITRIC OXIDE-DONATING STATINS EXERT BENEFICIAL EFFECTS ON ACUTE VASCULAR INFLAMMATION IN NORMOCHOLESTEROLEMIC RABBITS 241
Inhibition of smooth muscle cell migration and proliferation by statins 240
3-Aryl-N-aminoylsulfonylphenyl-1H-pyrazole-5-carboxamides : a new class of selective Rac inhibitors 240
(5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets 235
2-Amino-3-(phenylsulfanyl)norbornane-2-carboxylate : an Appealing Scaffold for the Design of Rac1-Tiam1 Protein-Protein Interaction Inhibitors 235
Fibrillar collagen inhibits cholesterol biosynthesis in human aortic smooth muscle cells 234
Pro-inflammatory cytokines and adipokines regulate PCSK9 expression in HepG2 cells 234
Aliskiren inhibits prorenin-induced human aortic smooth muscle cell migration 233
SOCS-3 induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line: a potential link between hypertriglyceridemia and insulin resistance 232
Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A Reductase inhibitors 231
Effect of genotype and diet on carotid lesions induced by perivascular collar placement in apoE-/- and wild-type mice 230
Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? 230
Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase 229
Purification and in vitro evaluation of an anti-HER2 affibody-2 monomethyl auristatin E conjugate in HER2-positive cancer cells 229
Statin drug interactions and related adverse reactions 228
In vitro and in vivo studies of antiatherosclerotic properties of everolimus 227
Impact of cigarette smoke on vascular smooth muscle cell senescence 224
SOCS-3 induces PCSK9 expression in hepatic HepG2 cell line 224
Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance 223
Everolimus affects cholesterol homeostasis in macrophages 220
Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia 220
Cyclosporine a impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion 219
Vascular myocytes preserve phenotypic features in culture 217
Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders 217
2024 consensus document of the Italian Society of Arterial Hypertension (SIIA) and the Italian Society of Cardiovascular Prevention (SIPREC): update on LDL cholesterol lowering in patients with arterial hypertension 216
PCSK9 expression is regulated by pro-inflammatory cytokines and adipokines in HEPG2 cells 215
Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice 215
STAT3 inhibition induces PCSK9 in hepatic cell line: possible involvement in hypertriglyceridemia associated with insulin resistance 212
Cigarette smoke and monocytes : a dangerous relationship for the endothelium? 211
STAT3 inhibition induces PCSK9 in hepatic cell line: possible involvement in hypertriglyceridemia associated with insulin resistance 211
Adipose tissue related adipokines and cytokines regulate PCSK9 expression in HepG2 cells 211
Farnesyltransferase inhibitors : CAAX mimetics based on different biaryl scaffolds 209
Novel compounds targeting PFKFB3, the key glycolytic enzyme, as a way to inhibit angiogenesis 209
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients 209
Totale 38.552
Salva come PNG Salva come JPEG
Categoria #
all - tutte 192.055
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 192.055
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021486 0 0 0 0 0 0 0 0 0 0 0 486
2021/20228.449 527 331 421 712 824 783 786 769 969 828 652 847
2022/20236.102 645 493 524 604 595 1.017 254 451 609 232 341 337
2023/20246.120 300 447 504 742 1.039 423 369 399 239 443 584 631
2024/202510.189 503 1.017 282 875 824 559 442 1.078 669 1.009 946 1.985
2025/202620.648 1.855 1.323 2.154 1.513 1.768 1.514 2.408 1.251 2.272 1.492 2.085 1.013
Totale 76.274